Trevi Therapeutics Inc (TRVI) Live Share Price, Invest From India

Trevi Therapeutics Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

Day's Low
Day's High
$10.25
Day's Price Range
$10.71
$10.64
3.67%
Downside
0.66%
Upside
52 Week's Low
52 Week's High
$4.85
52-Week Price Range
$14.39
$10.64
54.42%
Downside
35.24%
Upside

Trevi Therapeutics Inc share price movements today

Previous Close: $10.76
Open: $10.63
Volume: 1.3M
Day's Low - High: $10.25 - $10.71
52 Week Low - High: $4.85 - $14.39

Trevi Therapeutics Inc Historical Returns

1 Month Return: -5.28 %
3 Month Return: -17.04 %
1 Year Return: + 62.78 %
3 Year Return: 0 %
5 Year Return: 0 %

Trevi Therapeutics Inc Stock Fundamentals & Key Indicators

Check Trevi Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.4B

EPS (TTM)

-0.43

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-49.2M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-30.23%

Trevi Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Trevi Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Trevi Therapeutics Inc	BUY	$1.4B	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$41.4B	126.75%	133.41	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$115.3B	112.49%	29.68	32.94%
Beone Medicines Ltd	NA	$31.6B	NA	111	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$77.5B	58.91%	17.67	31.41%

Stock Returns calculator for Trevi Therapeutics Inc Stock including INR - Dollar returns

The Trevi Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Trevi Therapeutics Inc investment value today

Current value as on today

₹1,70,509

Returns

₹70,509

(+70.51%)

Returns from Trevi Therapeutics Inc Stock

₹60,968 (+60.97%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Trevi Therapeutics Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Trevi Therapeutics Inc. Average target price of $21.55

Trevi Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Trevi Therapeutics Inc.

What analysts predicted

50.63%UPSIDE

Target Price

$21.55

Current Price

$10.64

Analyzed by

12 Analysts

Target

$21.55

Trevi Therapeutics Inc target price $21.55, a slight upside of 50.63% compared to current price of $10.64. According to 12 analysts rating.

Trevi Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Trevi Therapeutics Inc Stock has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Time period: February 23, 2026 to March 25, 2026

Change:-47% versus previous 30 day period

Trevi Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	0	-	-	-	0	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	-
Operating Income	-9	-8	-11	-13	-14	-12	-11	-13	-13
EBITDA	-7	-7	-10	-12	-13	-11	-10	-12	-11
Interest Expense	0	0	0	0	0	0	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0
Income Before Tax	-7	-7	-10	-12	-13	-11	-10	-12	-11
Income Tax Expense	0	0	0	0	0	0	0	0	0
Net Income	-7	-7	-10	-12	-13	-11	-10	-12	-11
Net Profit Margin	0.00%	-4443.75%	0.00%	0.00%	0.00%	-7818.49%	0.00%	0.00%	0.00%

Trevi Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	-	-	-	-	-
Gross Profit	0	-	0	0	0	0	0	0	0
Operating Income	-8	-8	-18	-26	-32	-32	-29	-33	-51
EBITDA	-8	-8	-18	-26	-32	-32	-29	-28	-47
Interest Expense	-	3	0	0	0	1	0	0	0
Depreciation	-	0	0	0	0	0	0	0	0
Income Before Tax	-11	-12	-20	-26	-32	-33	-29	-29	-47
Income Tax Expense	0	0	0	0	0	0	0	0	0
Net Income	-11	-12	-20	-26	-32	-33	-29	-29	-47
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Trevi Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-7	-10	-12	-13	-11	-10	-12	-11	-8
Operating Cash Flow	-6	-10	-8	-9	-9	-13	-10	-10	-7
Investing Cash Flow	12	-8	2	7	-23	-9	-2	-50	-30
Financing Cash Flow	0	0	5	4	51	8	110	1	0
Change in Cash	6	-18	0	3	18	-14	97	-60	-37

Trevi Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-12	-20	-26	-32	-33	-29	-29	-47	-42
Operating Cash Flow	-7	-18	-23	-29	-28	-28	-31	-38	-42
Investing Cash Flow	0	0	0	0	-107	-107	59	-21	-94
Financing Cash Flow	21	0	73	16	20	111	-7	61	121
Change in Cash	13	-14	50	-12	-8	-24	19	1	-15

Global Institutional Holdings in Trevi Therapeutics Inc

Funds	Holdings
Octagon Capital Advisors LP	2.19%
Orbimed Advisors, LLC	2.58%
State Street Corp	1.73%
Affinity Asset Advisors, LLC	1.68%
Balyasny Asset Management LLC	1.93%

See all

Insights on Trevi Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, TRVI stock has moved up by 27.2%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, TRVI has outperformed top 5 stocks with highest market-cap in its industry

About Trevi Therapeutics Inc

trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can

Organisation	Trevi Therapeutics Inc
Headquarters	195 Church Street, New Haven, CT, United States, 06510
Industry	Pharmaceuticals: Major
CEO	Ms. Jennifer L. Good
E-voting on shares	Click here to vote

Key Management of Trevi Therapeutics Inc

Name	Title
Dr. James V. Cassella Ph.D.	Chief Development Officer
Dr. Thomas R. Sciascia M.D.	Co-Founder & Chief Scientific Officer
Mr. David C. Hastings CPA	Chief Financial Officer & Principal Financial Officer
Mr. Christopher Galletta	Controller & Chief Accounting Officer
Katie McManus	Communications Manager
Mr. Farrell Simon Pharm.D.	Chief Commercial Officer
Ms. Katherine Takaki Ph.D.	Senior VP of Global Regulatory Affairs
Ms. Jennifer L. Good	Co-Founder, CEO, President, & Director

FAQs

What is Trevi Therapeutics Inc share price today?

Trevi Therapeutics Inc share price today is $10.64 as on March 25, 2026 at 1:29 am IST at the close of the market. Trevi Therapeutics Inc share today touched a day high of $10.71 and a low of $10.25.

What is the 52 week high and 52 week low for Trevi Therapeutics Inc share?

Trevi Therapeutics Inc share touched a 52 week high of $14.39 on December 10, 2025 and a 52 week low of $4.85 on April 10, 2025. Trevi Therapeutics Inc stock price today i.e. March 25, 2026 at 1:29 am IST is closed at $10.64,which is 26.06% down from its 52 week high and 119.38% up from its 52 week low.

What is Trevi Therapeutics Inc's market capitalisation today?

Trevi Therapeutics Inc market capitalisation is $0.00T as on March 25, 2026 at 1:29 am IST.

How to invest in Trevi Therapeutics Inc Stock (TRVI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Trevi Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Trevi Therapeutics Inc Shares that will get you 0.1410 shares as per Trevi Therapeutics Inc share price of $10.64 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Trevi Therapeutics Inc Stock (TRVI) from India?

Indian investors can start investing in Trevi Therapeutics Inc (TRVI) shares with as little as ₹93.734 or $1 (as of March 25, 2026 at 7:40 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Trevi Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on March 25, 2026 at 7:40 am IST). Based on Trevi Therapeutics Inc share’s latest price of $10.64 as on March 25, 2026 at 1:29 am IST, you will get 0.9398 shares of Trevi Therapeutics Inc. Learn more about fractional shares .